Understanding the mechanisms behind squamous cell carcinomas

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This multicentric observational study involves 170 patients with squamous cell carcinoma (SCC) of the head and neck and anogenital tract. It aims to collect and analyze both retrospective and prospective samples to investigate molecular and viral biomarkers associated with SCC. Additionally, fibroblastic tumor-associated cells will be isolated from prospective samples to create 3D organoids for experimental assessment of responses to specific inhibitors. The study seeks to enhance understanding of SCC pathogenesis and treatment responses.

Why it matters

Who can join: the full rules

Inclusion Criteria:

Patients aged ≥ 18 years, candidates for surgical treatment for squamous cell carcinoma of the anus, uterine cervix, vulva, and head-neck region (including microinvasive and invasive carcinomas) who are capable of understanding and willing to sign the informed consent form. Prospective patients must provide written informed consent before any procedures.

Exclusion Criteria:

Patients presenting any of the following criteria are not eligible for inclusion in this study. Exclusion criteria include:

1. Metastatic neoplasia
2. Treatment for other oncological pathologies
3. Congenital or acquired immunosuppression (HIV, organ transplant, pharmacological)

Where it's running

• Istituto Tumori IRCCS Giovanni Paolo II di Bari
  Bari, Bari, Italy Recruiting
• Istituto Nazionale Tumori | "Fondazione Pascale"
  Naples, Napoli, Italy Recruiting
• Università del Piemonte orientale
  Novara, Novara, Italy Recruiting
• Azienda Ospedaliera Universitaria Pisana
  Pisa, Pisa, Italy Recruiting

Study contacts

• Principal investigator: Maria Lina Tornesello, M.D. — IRCCS I.N.T. "G. Pascale"
• Study coordinator: Maria Lina Tornesello, M.D.
• Email: m.tornesello@istitutotumori.na.it
• Phone: 08117770588

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• IDP-001 in advanced or metastatic solid tumors (including head and neck and skin cancers)

  A first- and second-phase study will test IDP-001 in people with advanced or metastatic solid tumors to see if it is safe and tolerable and to look for signs of activity.

  Recruiting at 6 sites Phase 1/2 InduPro, Inc. · Los Angeles, California and 5 other locations · NCT07602842

• Ficerafusp alfa plus pembrolizumab before surgery for resectable head and neck squamous cell carcinoma

  This trial will test whether giving ficerafusp alfa together with pembrolizumab before surgery helps people with PD‑L1–positive, resectable, high‑risk head and neck squamous cell carcinoma.

  Recruiting at 2 sites Phase 2 Dana-Farber Cancer Institute · Boston, Massachusetts and 1 other locations · NCT07465276

• HPV DNA-guided chemoradiation with Retifanlimab for locally advanced anal cancer

  This study tests whether adjusting chemoradiation doses based on HPV ctDNA results and adding Retifanlimab after CRT can improve outcomes for adults with new, locally advanced anal cancer.

  Recruiting Phase 2 Case Comprehensive Cancer Center · Cleveland, Ohio and 1 other locations · NCT07425054

• Cisplatin-related (Ear) Hearing Loss and Balance Issues in Head and Neck Cancer Patients

  This observational study tests whether hearing loss, tinnitus, and balance problems occur in head and neck cancer patients treated with cisplatin chemoradiotherapy compared with those receiving only radiotherapy, including optional genetic tests for susceptibility.

  Recruiting Paracelsus Medical University · Nuremberg, Bavaria · NCT06929468

• Injecting a viral particle to treat head and neck cancer

  This study is testing a new virus injection to see if it can help treat head and neck cancer in different groups of patients.

  Recruiting Phase 1 VLP Therapeutics · Stanford, California · NCT06736379

• Neoadjuvant chemotherapy with a vaccine for HPV-related throat cancer

  This study is testing if a new vaccine combined with standard chemotherapy can help people with HPV-related throat cancer live longer and avoid radiation treatment.

  Recruiting Phase 2 National Institutes of Health Clinical Center (CC) · Bethesda, Maryland · NCT06223568

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.